Why Did Germany Reject OTC Switch Of Low-Cost Smoking Cessation Drug Cytisine?

At its first meeting of 2023, Germany's switch committee voted against switching to OTC status low-cost smoking cessation drug cytisine. Complex treatment guidelines and concerns about side effects were among the considerations leading to this decision, the recently published minutes show.

smoking cigarette in the hand of young man close up

Complex treatment guidelines and concerns about side effects prevented Germany’s independent Expert Committee on Prescription (SVA) from recommending the Rx-to-OTC switch of smoking cessation drug cytisine, according to recently published minutes.

A nicotine-like generic alkaloid that occurs naturally in the laburnum plant species, cytisine potentially offers a low-cost alternative cessation

More from Europe

More from Geography